Prostate Cancer - Results from #1440

Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL). January 31, 2024

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer. January 31, 2024

Updates on Management of Biochemical Recurrent Prostate Cancer. January 31, 2024

Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations. January 30, 2024

PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence. January 30, 2024

Single port robot-assisted radical and simple prostatectomy: a systematic review and meta-analysis. January 30, 2024

Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images. January 30, 2024

Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study. January 30, 2024

Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort. January 29, 2024

Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. January 29, 2024

The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate Biopsy. January 29, 2024

15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis. January 29, 2024

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). January 29, 2024

Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer. January 29, 2024

Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial. January 29, 2024

The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer. January 29, 2024

Interactive training workshop to improve prostate mpMRI knowledge: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship. January 26, 2024

Functional Outcomes After Localized Prostate Cancer Treatment. January 26, 2024

Impact of PSMA PET on Prostate Cancer Management. January 26, 2024

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). January 26, 2024

Page 73 of 1436